Risk of seizure
PreclinicalSmall molecule
AstraZenecaRisk of seizure is one of 55 small molecule programs targeting Peptic ulcer. It is currently in Preclinical.
2
Indications
5
Total Trials
0
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
33 competitors in Seizure
#DrugCompanyPhaseTrials
1Keppra
UCBApproved
Vimpat
UCBApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Epidiolex
Jazz PharmaceuticalsApproved
Tegretol
NovartisApproved
Trileptal
NovartisApproved
Fycompa
CCatalyst Biosciences
Approved
Zonegran
AAzurity Pharmaceuticals
Approved
Dilantin
VViatris Specialty LLC
Approved
Topamax
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Clopidogrel1 trial
ESS1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Risk of seizure. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company